Disease burden high for adolescents with atopic dermatitis
Several new studies indicate that disease burden may be higher in adolescents than in adults with atopic dermatitis, and that adolescents with moderate-to-severe disease may face an even greater unmet therapeutic need.
 
ADVERTISEMENT
FDA grants priority review for dupilumab in pediatric AD
The FDA announced it has accepted a priority review of dupilumab for the treatment of moderate-to-severe AD in pediatric patients 6 to 11 years of age. The drug is already approved for treatment of AD in adolescents and adults.